ASSOCIATION OF ANXIETY DISORDER IN WOMEN WITH POLYCYSTIC OVARIAN SYNDROME Sumbul Sohail 1, Rubina Salahuddin 1, Shabnum Nadeem 1

Similar documents
Psychological impact of Polycystic Ovary Syndrome (PCOS)

Dr Stella Milsom. Endocrinologist Fertility Associates Auckland. 12:30-12:40 When Puberty is PCO

Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018

12/27/2013. Kristen Cain, MD FACOG Reproductive Medicine Institute Sanford Health, Fargo ND

What is PCOS? PCOS THE CONQUER PCOS E-BOOK. You'll be amazed when you read this...

Prevalence and implications of anxiety in polycystic ovary syndrome: results of an internet-based survey in Germany

Polycystic Ovary Syndrome (PCOS):

Risk of Developing Polycystic Ovarian Syndrome- Adolescent Girls

12/13/2017. Important references for PCOS. Polycystic Ovarian Syndrome (PCOS) for the Family Physician. 35 year old obese woman

Fertility problems in women with polycystic ovary syndrome

Polycystic Ovary Syndrome

Quality of life and marital sexual satisfaction in women with polycystic ovary syndrome

Overview of Reproductive Endocrinology

The Impact of Insulin Resistance on Long-Term Health in PCOS

New PCOS guidelines: What s relevant to general practice

A STUDY OF CLINICAL PARAMETERS IN THE DIAGNOSIS OF POLYCYSTIC OVARIAN SYNDROME Soumya Ranjan Panda 1, K. Durgavati 2, Santhosh Kumar Sahu 3

Nitasha Garg 1 Harkiran Kaur Khaira. About the Author

Polycystic ovary syndrome (PCOS)

Determining the insulin resistance rate in Polycystic Ovary Syndrome patients (PCOs)

The Relation between Diverse Phenotypes of PCOS with Clinical Manifestations, Anthropometric Indices and Metabolic Characteristics

Anuja Dokras, MD., PhD. Professor Obstetrics and Gynecology Director PENN PCOS Center University of Pennsylvania, USA.

Polycystic Ovarian Syndrome. Heidi Hallonquist, MD Concord Hospital Concord Obstetrics and Gynecology

UNDERSTANDING PCOS AND ITS DIAGNOSIS

Polycystic Ovary Syndrome

Scope. Update and expansion of Evidence-based guideline for the assessment and management of PCOS. Clinical context

health in women with PCOS

ROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU)

Reproductive Health in Non Alcoolic Fatty Liver Disease (NAFLD)

Polycystic Ovary Syndrome: Cardiovascular Disease risk

PCOS Awareness Symposium Atlanta September 24 th, Preventing Diabetes & Cardiovascular Disease in PCOS

Polycystic Ovary Syndrome (PCOS)

Study of clinical presentation in cases of Polycystic Ovarian Syndrome in rural population

Abnormal Uterine Bleeding Case Studies

METABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN MORPHOLOGY

Information for you. What is polycystic ovary syndrome? Polycystic ovary syndrome: what it means for your long-term health

Metabolic syndrome in females with polycystic ovary syndrome and International Diabetes Federation criteria

Case Questions. Polycystic Ovarian Syndrome: Treatment Goals and Options. Differential Diagnosis of Hyperandrogenic Anovulation

PCOS guidelines: What s relevant to general practice

ASK PCOS. Evidence-based information for women with Polycystic ovary syndrome

PCOS IN ADOLESCENTS: EARLY DETECTION AND INTERVENTION

Clinical Profile Polycystic Ovarian Syndrome Cases

S. AMH in PCOS Research Insights beyond a Diagnostic Marker

Prevalence and symptomatology of polycystic ovarian syndrome in Indian women: is there a rising incidence?

PCOS and Obesity DUB is better treated by OCPs

Female Reproductive Endocrinology

Obstretics and Gynaecology. Nikita M. Singh A, Deepak Kamat B, Parth Patel A, Tupe N.B C

Psychosocial Aspects of PCOS. Andrea Mechanick Braverman, PhD

Polycystic Ovarian Syndrome (PCOS) LOGO

Infertility Treatment in Polycystic Ovary Syndrome: Lifestyle Interventions, Medications and Surgery

What is polycystic ovary syndrome? What are polycystic ovaries? What are the symptoms of PCOS?

SCREENING OF POLYCYSTIC OVARIAN SYNDROME AMONG ADOLESCENT GIRLS AT CAIRO UNIVERSITY

What is PCOS? Key Points. Definition. Key Signs + Symptoms. Typical Experiences 10/29/2017

Prevalence of Polycystic Ovarian Syndrome among urban adolescent girls and young women in Mumbai

Research article. Journal of Biotechnology and Biosafety Volume 4, Issue 6, November-December 2016,

Polycystic Ovary Disease: A Common Endocrine Disorder in Women

Awareness of PCOS (polycystic ovarian syndrome) in adolescent and young girls

POLYCYSTIC OVARIAN SYNDROME Laura Tatpati, MD Reproductive Endocrinology and Infertility. Based on: ACOG No. 108 Oct 2009; reaffirmed 2015

Pregnancy outcome in women with polycystic ovary syndrome

International Academy of Engineering and Medical Research, 2018 Volume-3, Issue-1 Published Online January 2018 in IAEMR (

WHY NEW DIAGNOSTIC CRITERIA FOR DIFFERENT PCOS PHENOTYPES ARE URGENTLY NEEDED

About PCOS. About PCOS

International Journal of Current Medical And Applied Sciences.vol.1. Issue: 1, 2013, PP 11-15

Amenorrhoea: polycystic ovary syndrome

Polycystic Ovary Syndrome

THYROID PROFILE IN POLYCYSTIC OVARIAN SYNDROME Sudhanshu Sekhara Nanda 1, Subhalaxmi Dash 2, Ashok Behera 3, Bharati Mishra 4

UPDATE: Women s Health Issues

13 th Annual Women s Health Day PCOS. Saturday 02/09/2017 Dr Mathias Epee-Bekima O&G Consultant KEMH

JMSCR Vol 05 Issue 05 Page May 2017

A study of N-acetyl cysteine, metformin and vitamin D3 with calcium on clinical and metabolic profile in PCOS

Polycystic Ovary Syndrome

Awareness of Polycystic Ovarian Disease among Females of Age Group Years

CREATING A PCOS TREATMENT PLAN. Ricardo Azziz, M.D., M.P.H., M.B.A. Georgia Regents University

Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc)

PharmaTutor PRINT ISSN: E-ISSN:

3. Metformin therapy for PCOS

Estimation and occurrence of polycystic ovary among Sudanese woman's 2018

The Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (1), Page 63-69

Polycystic ovarian syndrome Can lifestyle modifications help?? Dr Saloni Assistant Professor, Deptt of OBG BPSGMC for Women, Khanpur Kalan

Gonadotrophin treatment in patients with Polycystic Ovary Syndrome

What every dermatologist should know about Polycystic Ovary Syndrome (PCOS)

Does Ovarian Cysts affect your Fertility?

ASSOCIATION OF INSULIN RESISTANCE AND SERUM 25 OH VITAMIN-D IN INDIAN WOMEN WITH POLYCYSTIC OVARY SYNDROME

Iranian version of modified polycystic ovary syndrome health-related quality of Life questionnaire: Discriminant and convergent validity

Prevalence of polycystic ovarian syndrome in the Buraimi region of Oman

Polycystic Ovary Syndrome (PCOS)

Cam type Femoroacetabular Impingement associated with Marker for Hyperandrogenism in Women

METABOLIC SYNDROME IN REPRODUCTIVE FEMALES

JMSCR Vol 05 Issue 04 Page April 2017

F REQUENTLY A SKED Q UESTIONS

The prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria

A study of clinical manifestations of PCOS among obese and non- obese rural women

Addressing Practice Gaps in PCOS

Anxiety and depression symptoms in women with polycystic ovary syndrome compared with controls matched for body mass index

Manipal & Apollo Spectra Hospital. Special Interest:Laparoscopy & Bariatric Surgery

Vitamin D Levels in Women with Polycystic Ovary Syndrome

CHAPTER VI SUMMARY AND CONCLUSIONS

Metfornim and Pioglitazone in polycystic ovarian syndrome: A comparative study

Diabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome

Polycystic ovary syndrome

Polycystic Ovary Syndrome

Transcription:

ORIGINAL ARTICLE ASSOCIATION OF ANXIETY DISORDER IN WOMEN WITH POLYCYSTIC OVARIAN SYNDROME Sumbul Sohail 1, Rubina Salahuddin 1, Shabnum Nadeem 1 ABSTRACT 1 Gynae Unit 2 Kmdc Abbasi Shaheed Hospital Karachi Background: Association of anxiety disorders in women with polycystic ovarian syndrome Association of Clinical and metabolic features of PCOD with anxiety Methods: A comparative cross sectional study was conducted for a one year period from October 213-October 214.2 control subjects were compared with 2 patients with aged 18-35using Rotterdam Criteria. Anxiety and depression symptoms were assessed using the HADS questionnaire. Results: Anxiety and depression disorders were significantly higher in as compared to control p value (<.1). Anxiety was associated with hirsutism p value (<.1 and obesity p value (<.3).However, no association was found between abnormal lipid profiles and altered fasting blood sugar levels. Conclusion: Women with experience elevated anxiety and depression. Other aspects like weight reduction, behavioral therapy need to be emphasized for a healthy life style. KEY WORDS: anxiety, acne, hirsutism, quality of life INTRODUCTION Polycystic ovary syndrome is an endocrine disorder among women of reproductive age of unknown etiology and is genetic in nature. These women experience the following: Infrequent or prolonged menstrual periods Excess hair growth Acne and obesity Ultrasound may show enlarged ovaries containing small collection of follicles. Early diagnoses and weight reduction may help in preventing metabolic syndrome.anxiety and depression has been reported in women with PCOD 1.Risk factors include Type 1 and Type 2 diabetes. Infertility, gestational diabetes,cardio-metabolic abnormalities such as dyslipidemia, insulin resistance.the diagnosis of polycystic syndrome is confirmed on the basis of Modified Rotterdam criteria, i.e. the presence of two of the following criteria: 1. Oligomenorrhoea 2. Hyperandrogenism 3. Polycystic ovaries assessed by ultrasound Women having polycystic ovarian syndrome are associated with anxiety, depression and eating disorders in comparison with normal ovulating, non-hyper-androgenic women 1.The pathophysiology remains unclear. There are several reports linking PCOD features; acne, obesity, infertility and hirsutism to psychological morbidities 3. Although anxiety appears to be the most common psychiatric diagnosis among patients with endocrine diseases 4 there is limited data to prove this 3, 4 5 6.The acute distress of not having a family, and obesity may lead to anxiety, depression, and eating disorders, resulting in isolation, quality of life impairment and increased risk of psychiatric disorders. However, research is needed to find association of anxiety and depression before patient can be treated 5, 7. Mansson etal recently reported that the life time incidence of social phobia was 27% while Kerchner etal documented a prevalence of 11.6% 11.Additional data suggests that clinician should screen women with PCOD for anxiety and depression disorders 9, 1.As are characterized by heterogeneity in clinical and metabolic characteristics 1, it could be suggested that clinical, hormonal and metabolic parameters could be responsible for this. Our current study presented clinical and metabolic features of and their relationship with anxiety and depression. METHODS Design, Sample and Setting This was a comparative cross sectional study. Ethical approval was obtained from Ethical Review Committee of CDGK. The Chief investigator (who was also the clinical examiner) provided written and verbal consent from the participating women and 2 patients aged 18-35 years were diagnosed as and 2 controls. Corresponding Author: Sumbul Sohail * PAKISTAN JOURNAL OF MEDICINE AND DENTISTRY 216, VOL. 5 (1) 41

SUMBUL SOHAIL, RUBINA SALAHUDDIN, SHABNUM NADEEM Exclusion Criteria 1.Use of metformin in the 6 days prior to enrollment 2.Pregnant or breastfeeding 3.Coagulation disorders 4.Any psychological disorders 5.Diabetic and hypertensive Control subjects were randomly selected from women who had regular menses and absence of familial hirsutism. The data was collected by completing two questionnaires (in different regional languages), followed by clinical examination, ultrasound and laboratory investigation.the degree of hirsutism was evaluated by the FG score. Anthropometrics included body weight, body height, waist and hip circumference. Body weight and body height were measured in an upright position with light clothing and no shoes. BMI was calculated as bodyweight (kg) divided by body height (m) 2.Waist circumference was measured in centimeters at the mid-point between the iliac crest and lower rib margin at the end of expiration. Hip circumference was measured in centimeters at the widest point between waist and thigh. WHR (Waist/Hip ratio) was calculated as the ratio of waist and hip circumference. Endocrine parameter were measured during follicular phase of menstrual cycle, lipid profile with 14 hours of fasting. The demographic questionnaire (details found in Table 1) designed specific categories. Anxiety and depression symptoms were assessed using the Hospital Anxiety and Depression Scale (HADS) questionnaire. The participants self-reported the severity and frequency of symptoms. The sensitivity is (83.3%) and specificity (61.5%) for the identification of psychiatric cases. DATA ANALYSIS The data were analyzed from two questionnaires, clinical examination findings, and lab results. Continues variables were analyzed using a two-tailed t-test. Chi-square test were used to evaluate categorical variables of anxiety disorders between subjects with and control subjects and correlation between anxiety disorders, hyperandrogenism, hormonal and other metabolic profile of patients with. The correlation were statistically significant at the level of a p value of.5 or less. RESULT (n=2) and control(n=2) completed the questionnaire. The demographic characteristics and potential moderators for anxiety disorders are shown in Table 1.56(28%) were unmarried and control group 44(22%) and most patients with were highly educated as compared to control group (p value=.2). were more prevalent in nulliparous women. and women were using medications to either conceive or correct their problems like menstrual irregularities, weight gain etc.(p value=<.1). Table1 shows no difference in employment status, psychiatric illness, family history of diabetes, and eating habits of and control group. PCOD patients indulged in more physical activities compared to control subjects (p value=<.1). PCOD patients were more obese as compared to the control (p value=.1).table 2:Anxiety and depressive disorders were significantly higher in compared to the control (p value=<.1).table 3 shows that there was no relationship between demographic data of patients with anxiety disorders. Significant association was found in patients having hirsutism with anxiety as compared to control group (p value =.1).Patients with hirsutism were more anxious and visited more frequently for treatment. To examine the role of obesity, we found that anxiety disorders were more prevalent among PCOD obese women (p value=.3). This is because obese women tend to stay away from social gatherings, leading to withdrawal and isolation. BMI has a great influence on quality of life too. Table 3 shows anxiety symptoms were associated with PCOD patients who had a higher BMI compared to normal BMI (p value=<.1).table 3shows there was no association between anxiety disorders and deranged fasting blood sugar and lipid profile. Table1-Comparisonof Demographic & History Data for Women with & without With (n=2) Without (n=2) p-value Age (years), mean + SD Un married 26.6 + 5.1 27.5 + 5.2 56 (28%) 44 (22%).62 Marital Status of patient MArried Separated 135 (67.5%) 144 (72%) 4 (2%) 8 (4%).397 Divorced 4 (2%) 2 (1%) Widow 1 (.5%) 2 (1%) 42 PAKISTAN JOURNAL OF MEDICINE AND DENTISTRY 216, VOL. 5 (1)

ASSOCIATION OF ANXIETY DISORDER IN WOMEN WITH POLYCYSTIC OVARIAN SYNDROME literacy 32 (16%) 4 (2%) Literacy of the patient Primary 33 (16.5%) 58 (29%).2 Secondary 135 (67.5%) 12 (51%) Unemployment 149 (74.5%) 148 (74%) Employment of the patient Employed full time 19 (9.5%) 6 (3%).1 Employed part time 32 (16%) 46 (23%) Unmarried 59 (29.5%) 45 (22.5%) Obstetrical history Nulliparous 87 (43.5%) 5 (25%) <.1 Multiparous 54 (27%) 15 (52.5%) 6 (3%) 11 (5.5%) Psychiatric illness history 194 (97%) 189 (94.5%).15 Metformin 11 (5.5%) 3 (1.5%) Hormonal contraceptive 1 (5%) 1 (.5%) Drug history of the patient Anti-psychotic 3 (1.5%) 147 (73.5%) 194 (97%) <.1 Ovulation induction 22 (11%) 2 (1%) 1+2 7 (3.5%) Table 2- Comparision of Anxiety & Depression in Women with & without With (n=2) Without (n=2) p-value Anxiety Anxiety >8 159 (79.5%) 34 (17.5%) <8 41 (25%) 16 (82.58%) <.1 Depression >8 1 (5%) 35 (18%) <.1 Depression <8 1 (5%) 159 (82%) PAKISTAN JOURNAL OF MEDICINE AND DENTISTRY 216, VOL. 5 (1) 43

SUMBUL SOHAIL, RUBINA SALAHUDDIN, SHABNUM NADEEM Table 3- Comparison od Demographic & History Data for Women with & without Anxiety Women with Anxiety (n=159) Women without Anxiety (n=159) p-value Age (years), mean + SD Un married 26.9 + 5.1 4 (25.2%) 25.9 + 5..91 16 (39%) Marital status of patient Married Separated 11 (69.2%) 4 (2.5%) 25 (61%) Divorced Window 4 (2.5%) 1 (.6%) Literacy of patient literacy Primary Secondary 31 (19.5%) 28 (17.6%) 1 (62.9%) 1 (2.4%) 5 (12.2%) 35 (85.4%).11 Unemployment 12 (75.5%) 29 (7.7%) Employment of the patient Employed full time Employed Part time 14 (8.8%) 25 (15.7%) 5 (12.2%) 7 (17.7%).767 Unmarried 42 (26.4%) 17 (41.5%) Obstetrical history Nulliparous 76 (47.8%) 11 (26.8%).45 Multiparous 41 (25.8%) 13 (31.7%) Psychiatric illness history 6 (3.8%) 153 (96.3%) 41 (1%).27 Metformin 1 (6.3%) 1 (2.4%) Hormonal contraceptive 8 (5%) 2 (4.9%) Drug history of the patient Anti-psychotic 3 (1.9%) 114 (71.7%) 33 (8.5%).569 Ovulation induction 17 (1%) 5 (12.2%) 1+2 7 (4.4%) 5 (3.1%) 1 (2.4%).813 44 PAKISTAN JOURNAL OF MEDICINE AND DENTISTRY 216, VOL. 5 (1)

ASSOCIATION OF ANXIETY DISORDER IN WOMEN WITH POLYCYSTIC OVARIAN SYNDROME Family history of psychlatric illness 5 (3.1%) 1 (2.4%) 154 (69.9%) 4 (97.6%).813 Family history of diabetes 61 (38.4%) 8 (19.5%) 98 (61.6%) 33 (8.5%).24 Menstrual calender of patient rmal cycle Short cycle 47 (29.6%) 1 (24.4%) 4 (2.5%) 1 (2.4%) Prolong cycle 18 (67.9%) 3 (73.2%) Carbohydrate 26 (16.4%) 7 (17.1%) Eating habit of the patient/daymostly Protein Fat Mix 1 (.6%) 1 (.6%) 131 (82.4%) 34 (82.9%).913 Physical acvtivity of the patient Sedentary life Walking>i hour Aerobic exercises 46 (28.9%) 93 (58.5%) 2 (12.6%) 9 (22%) 25 (61%) 7 (17.1%).577 Acanthosis nigrican of patient 124 (78%) 35 (22%) 26 (63.4%) 15 (36.6%).55 Hirsutism 148 (93.1%) 11 (6.9%) 31 (75.6%) 1 (24.4%).1 Alopecia 59 (37.1%) 1 (62.9%) 9 (22%) 32 (78%).68 Acne 53 (33.3%) 16 (66.7%) 17 (41.5%) 24 (58.5%).33 Height (cm), mean + sd Weight (kg), mean + sd BMI, mean + sd Waist (cm), mean + sd Hip(cm), mean + sd Waist-hip ratio, mean + sd Fasting blood sugar, mean + sd 155.1 + 5.7 155.3 + 6.9 73.9 + 13.9 64.3 + 14. 3.5 + 5.2 27.1 + 4.6 92.4 + 15.2 84.7 + 11.8 18.4 + 16.311.7 + 11.4.85 +.6.83 +.7 89. + 8.7 87. + 6.9.887.3 <.1.2.28.18.13 Lipid Profile rmal Increased 124 (78%) 4 (97.6%) 35 (22%) 1 (2.4%).4 PAKISTAN JOURNAL OF MEDICINE AND DENTISTRY 216, VOL. 5 (1) 45

SUMBUL SOHAIL, RUBINA SALAHUDDIN, SHABNUM NADEEM DISCUSSION Our study found that was there was a higher anxiety score in women with PCOD than in control. Another study showed an increased association between metabolic and hormonal profile 1.Patients recruited had no previous health care contact and rigorous inclusion and exclusion criteria was used. A large proportion of women PCOD had anxiety which suggests that there is a definite need for treatment and/or counseling 1.Signs of anxiety and depression need to be evaluated before we start treating patients 7. A life time diagnosis of generalized anxiety disorder (GAD) in 17% of 11.It remains unclear what factors maintain a high level of anxiety in PCOD women. Cycle disturbance and infertility may interfere with normal female role expectations which contribute to social fears and withdrawal. Hirsutism93%, acne 53%, obesity3.5%, and76%had anxiety related symptoms. However, our data cannot exclude that elevated anxiety was attributed to the emotional sequels of unsuccessful infertility treatment. Some authors have suggested that adolescents with are at a higher risk of anxiety symptoms due to hyperandrogenism, as treatment of hirsutism has shown is associated with an improvement in the anxiety score 8.In our study high BMI reported a higher generalized anxiety.in an internet study using HADS, anxiety was more common in those with acne than those with an unfulfilled wish for conception. CONCLUSION is a highly heterogeneous disease. Therapy should focus on both short term and long term reproductive, metabolic and psychological features. It s important to look into the psychological aspects so as to bring about such changes that would improve the quality of life. Screening, assessment and treatment of anxiety and depression are important. Treatment should include other aspects of emotional wellbeing, like obesity, disordered eating. Management should not only focus on targeted treatment but education and counselling for a healthy life style. Social support groups should be established. REFERENCES 1. Livadas S, Chaskon S, Kandaraki A A, Christout M, Anna K. kandarakist ED, Anxiety is associated with hormonaland metabolic profile in women with polycystic ovarian syndrome.j Clinical Endocrinology 211; 75: 698-73. 2.Sonino N C, Ruini C, et al., Persistent Psychological distress in patients treated for endocrine diseases. Psychotherapy Psychosomatics 24; 73:78-83 3.Elsenbruch S, Hahn S, Kowalsky D. et al., Quality of life, psychosocial well-being, and sexual satisfaction in women with poly cystic ovary syndrome. Journal of clinical Endocrinology and Metabolism 23; 88: 581-587. 4.Mansson M, Holte J, Landin-Wilhelmsen K, et al., Women with polycystic ovary syndrome are often depressed or anxious-a case control study. Psychoneuro Endocrinology 28; 33:1132-1134. 5. Kaufman J, Charney D. Comorbidity of mood and anxiety disorder. Depression and anxiety 2; 12 : 69-76. 6. Benson S, Hahn S, Tan S, Mann K, Janssen OE, Schedlowski M, and Elsenbruch S. Prevalence and implications of anxiety in poly cystic ovary syndrome: results of an internet-based survey in Germany. Human Reproduction, 29; 24(6):1446-1451 7. Screen for Anxiety, Mood Disorders in All Women with PCOS: Study. Fertility and Sterility 212. 8.Sam S,Dunaif A. polycystic ovary syndrome: Syndromexx: Trends of Endocrinology and Metabolism 23;14,365-37. 9.Hollinrake E, Abreu A, Maifeld M, Van Voorhis BJ, Dokras A. Increased risk of anxiety and depressive disorders in women with polycystic ovary syndrome, Fertility and Sterility 27; 87(6): 1369 76 1 Moran LJ, Deeks AA, Gibson-Helm ME, and Teede HJ. Psychological parameters in the reproductive phenotypes of polycystic ovary syndrome. Hum. Reprod. Psychology and Counselling, 212; 27 (7): 282-288 11. Kerchner A, Lester W, Stuart SP, Dokras A. Polycystic ovary syndrome. Risk of depression and other mental health disorders in women with polycystic ovary syndrome, Fertility and Sterility 29; 91(1): 936 949 46 PAKISTAN JOURNAL OF MEDICINE AND DENTISTRY 216, VOL. 5 (1)